ClinicalTrials.gov record
Completed Phase 3 Interventional

Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma

ClinicalTrials.gov ID: NCT00324727

Public ClinicalTrials.gov record NCT00324727. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 18, 2026, 4:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Random-Assignment Study of Hepatic Arterial Infusion of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) (Delcath System) Versus Best Alternative Care for Ocular and Cutaneous Melanoma Metastatic to the Liver

Study identification

NCT ID
NCT00324727
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Delcath Systems Inc.
Industry
Enrollment
93 participants

Conditions and interventions

Interventions

  • hepatic artery embolization Procedure
  • melphalan Drug
  • regional chemotherapy Drug
  • systemic chemotherapy Drug

Procedure · Drug

Eligibility (public fields only)

Age range
18 Years to 120 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2006
Primary completion
Jul 31, 2012
Completion
Jul 31, 2012
Last update posted
Jun 20, 2021

2006 – 2012

United States locations

U.S. sites
12
U.S. states
10
U.S. cities
12
Facility City State ZIP Site status
John Wayne Cancer Institute at Saint John's Health Center Santa Monica California 90404
Swedish Medical Center Englewood Colorado 80113
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida Tampa Florida 33612-9497
Greenebaum Cancer Center at University of Maryland Medical Center Baltimore Maryland 21201
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office Bethesda Maryland 20892-1182
Carol G. Simon Cancer Center at Morristown Memorial Hospital Morristown New Jersey 07962-1956
Cancer Center of Albany Medical Center Albany New York 12208
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center Columbus Ohio 43210-1240
Providence Cancer Center at Providence Portland Medical Center Portland Oregon 97213-2967
St. Luke's Cancer Network at St. Luke's Hospital Bethlehem Pennsylvania 18015
UPMC Cancer Centers Pittsburgh Pennsylvania 15232
University of Texas Medical Branch Galveston Texas 77555-0361

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00324727, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 20, 2021 · Synced May 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00324727 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →